These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19. Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898 [No Abstract] [Full Text] [Related]
3. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578 [TBL] [Abstract][Full Text] [Related]
4. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Parums DV Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 Updates: Monoclonal Antibodies for COVID-19. Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286 [No Abstract] [Full Text] [Related]
6. COVID-19 update: NIH recommends against ivermectin. Med Lett Drugs Ther; 2022 Jun; 64(1652):95-96. PubMed ID: 35657909 [No Abstract] [Full Text] [Related]
7. Table: Treatments considered for COVID-19. Med Lett Drugs Ther; 2020 Apr; 62(1595):e1-e280. PubMed ID: 35081103 [No Abstract] [Full Text] [Related]
8. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
9. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E Elife; 2022 Nov; 11():. PubMed ID: 36413383 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 updates: FDA restricts use of sotrovimab. Med Lett Drugs Ther; 2022 Apr; 64(1648):64. PubMed ID: 35436778 [No Abstract] [Full Text] [Related]
11. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686 [TBL] [Abstract][Full Text] [Related]
12. An EUA for sotrovimab for treatment of COVID-19. Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630 [No Abstract] [Full Text] [Related]
13. An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966 [No Abstract] [Full Text] [Related]
14. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). Qaseem A; Yost J; Miller MC; Andrews R; Jokela JA; Forciea MA; Abraham GM; Humphrey LL; ; Lee RA; Tschanz MP; Etxeandia-Ikobaltzeta I; Harrod C; Shamliyan T; Umana K Ann Intern Med; 2023 Jan; 176(1):115-124. PubMed ID: 36442061 [TBL] [Abstract][Full Text] [Related]
15. Treatment of COVID-19 in high-risk outpatients. Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051 [No Abstract] [Full Text] [Related]
16. An EUA for bebtelovimab for treatment of COVID-19. Med Lett Drugs Ther; 2022 Mar; 64(1646):41-42. PubMed ID: 35294426 [No Abstract] [Full Text] [Related]